Litigation
BioMarin Pharmaceutical Inc. v. Ascendis Pharma, Inc. et al.
settled/dismissed337-TA-1447
Auto-generating section 1 of 5: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Filed
- 2025-04-02
Patents at issue (2)
Plaintiffs (1)
Summary
ITC Section 337 investigation titled Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof, brought by BioMarin against Ascendis entities and suppliers regarding TransCon CNP / navepegritide. The asserted patent was U.S. Reissue Patent No. RE48,267; US 8,377,884 was relied on by Ascendis as prior-art Exhibit 32, not asserted. Resolved by a global settlement announced August 30–31, 2026, with the investigation to be dismissed.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
In the news
What the press has reported about this case, summarized with links to the source articles.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).